false 0000899923 12/31 2022 Q3 1 P1Y 0000899923 2022-01-01 2022-09-30 0000899923 2022-10-27 xbrli:shares 0000899923 2022-09-30 iso4217:USD 0000899923 2021-12-31 0000899923 mygn:MolecularDiagnosticTestingMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTestingMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTestingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTestingMember 2021-01-01 2021-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2022-07-01 2022-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2021-07-01 2021-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2022-01-01 2022-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2021-01-01 2021-09-30 0000899923 2022-07-01 2022-09-30 0000899923 2021-07-01 2021-09-30 0000899923 2021-01-01 2021-09-30 iso4217:USD xbrli:shares 0000899923 us-gaap:CommonStockMember 2020-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000899923 us-gaap:RetainedEarningsMember 2020-12-31 0000899923 us-gaap:NoncontrollingInterestMember 2020-12-31 0000899923 2020-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000899923 2021-01-01 2021-03-31 0000899923 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000899923 us-gaap:CommonStockMember 2021-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000899923 us-gaap:RetainedEarningsMember 2021-03-31 0000899923 us-gaap:NoncontrollingInterestMember 2021-03-31 0000899923 2021-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000899923 2021-04-01 2021-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000899923 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000899923 us-gaap:CommonStockMember 2021-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000899923 us-gaap:RetainedEarningsMember 2021-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2021-06-30 0000899923 2021-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000899923 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000899923 us-gaap:CommonStockMember 2021-09-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000899923 us-gaap:RetainedEarningsMember 2021-09-30 0000899923 us-gaap:NoncontrollingInterestMember 2021-09-30 0000899923 2021-09-30 0000899923 us-gaap:CommonStockMember 2021-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000899923 us-gaap:RetainedEarningsMember 2021-12-31 0000899923 us-gaap:NoncontrollingInterestMember 2021-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000899923 2022-01-01 2022-03-31 0000899923 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000899923 us-gaap:CommonStockMember 2022-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000899923 us-gaap:RetainedEarningsMember 2022-03-31 0000899923 us-gaap:NoncontrollingInterestMember 2022-03-31 0000899923 2022-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000899923 2022-04-01 2022-06-30 0000899923 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000899923 us-gaap:CommonStockMember 2022-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000899923 us-gaap:RetainedEarningsMember 2022-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2022-06-30 0000899923 2022-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000899923 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000899923 us-gaap:CommonStockMember 2022-09-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000899923 us-gaap:RetainedEarningsMember 2022-09-30 0000899923 us-gaap:NoncontrollingInterestMember 2022-09-30 mygn:segment 0000899923 country:US mygn:MolecularDiagnosticHereditaryCancerTestingMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2022-07-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-07-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticTumorProfilingMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2022-07-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticTumorProfilingMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2021-07-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticPharmacogenomicsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2022-07-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticPharmacogenomicsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2021-07-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticAutoimmuneMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2022-07-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticAutoimmuneMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2021-07-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticTestingMember 2022-07-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticTestingMember 2021-07-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 country:US 2022-07-01 2022-09-30 0000899923 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000899923 country:US 2021-07-01 2021-09-30 0000899923 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticHereditaryCancerTestingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-01-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticTumorProfilingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticTumorProfilingMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2021-01-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticPharmacogenomicsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticPharmacogenomicsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2021-01-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticAutoimmuneMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticAutoimmuneMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2021-01-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticOtherTestingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticOtherTestingMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2021-01-01 2021-09-30 0000899923 country:US mygn:MolecularDiagnosticTestingMember 2022-01-01 2022-09-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 country:US mygn:MolecularDiagnosticTestingMember 2021-01-01 2021-09-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 country:US mygn:PharmaceuticalAndClinicalServicesMember 2022-01-01 2022-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 country:US mygn:PharmaceuticalAndClinicalServicesMember 2021-01-01 2021-09-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 country:US 2022-01-01 2022-09-30 0000899923 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000899923 country:US 2021-01-01 2021-09-30 0000899923 us-gaap:NonUsMember 2021-01-01 2021-09-30 0000899923 2019-07-01 2020-06-30 0000899923 mygn:PerformanceObligationEstimatedTransactionPriceMember 2022-07-01 2022-09-30 0000899923 mygn:PerformanceObligationEstimatedTransactionPriceMember 2022-01-01 2022-09-30 0000899923 mygn:MedicareMember us-gaap:GovernmentContractsConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-07-01 2022-09-30 xbrli:pure 0000899923 mygn:MedicareMember us-gaap:GovernmentContractsConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-09-30 0000899923 mygn:MedicareMember us-gaap:GovernmentContractsConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2021-09-30 0000899923 mygn:MedicareMember us-gaap:GovernmentContractsConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-09-30 0000899923 us-gaap:CashMember 2022-09-30 0000899923 us-gaap:CashEquivalentsMember 2022-09-30 0000899923 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:MunicipalBondsMember 2022-09-30 0000899923 us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:CashMember 2021-12-31 0000899923 us-gaap:CashEquivalentsMember 2021-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:MunicipalBondsMember 2021-12-31 0000899923 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-09-30 0000899923 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-09-30 0000899923 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0000899923 us-gaap:MoneyMarketFundsMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2022-09-30 0000899923 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member mygn:ContingentConsiderationMember 2022-09-30 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0000899923 mygn:ContingentConsiderationMember 2022-09-30 0000899923 us-gaap:FairValueInputsLevel1Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel2Member 2022-09-30 0000899923 us-gaap:FairValueInputsLevel3Member 2022-09-30 0000899923 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000899923 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000899923 us-gaap:MoneyMarketFundsMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2021-12-31 0000899923 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member mygn:ContingentConsiderationMember 2021-12-31 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000899923 mygn:ContingentConsiderationMember 2021-12-31 0000899923 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000899923 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000899923 us-gaap:LeaseholdImprovementsMember 2022-09-30 0000899923 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000899923 us-gaap:EquipmentMember 2022-09-30 0000899923 us-gaap:EquipmentMember 2021-12-31 0000899923 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-09-30 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2022-09-30 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2021-12-31 0000899923 us-gaap:RevolvingCreditFacilityMember 2016-12-23 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2018-07-31 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-02-22 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-02-21 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-09-30 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-25 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 0000899923 mygn:AmendmentToCreditAgreementMember srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000899923 mygn:AmendmentToCreditAgreementMember 2022-07-26 2022-07-26 0000899923 us-gaap:LetterOfCreditMember mygn:AmendmentToCreditAgreementMember 2022-07-26 2022-07-26 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-01 2021-06-30 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2020-04-01 2021-06-30 0000899923 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 2022-07-26 0000899923 mygn:AmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-07-26 2022-07-26 0000899923 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-12-31 0000899923 2016-06-30 0000899923 mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember 2022-09-30 0000899923 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000899923 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000899923 mygn:OptionsAndRestrictedStockUnitsMember mygn:NonEmployeeDirectorMember 2022-01-01 2022-09-30 0000899923 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000899923 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-09-30 0000899923 us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000899923 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2022-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2021-09-23 2021-09-23 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2022-01-01 2022-09-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2022-07-01 2022-09-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2021-07-01 2021-09-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2022-01-01 2022-09-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2021-01-01 2021-09-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2022-07-01 2022-09-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2021-07-01 2021-09-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2022-01-01 2022-09-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2021-01-01 2021-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMember 2020-12-21 2020-12-21 mygn:patent 0000899923 srt:MinimumMember 2022-09-30 0000899923 srt:MaximumMember 2022-09-30 0000899923 mygn:WestSaltLakeCityLeaseMember 2022-03-31 utr:sqft 0000899923 mygn:WestSaltLakeCityLeaseMember 2022-09-30 0000899923 mygn:SouthSanFranciscoCaliforniaMember 2022-09-30 0000899923 mygn:MyriadMyPathLLCLaboratoryMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-05-28 2021-05-28 0000899923 mygn:MyriadMyPathLLCLaboratoryMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-04-01 2021-06-30 0000899923 mygn:MyriadAutoimmuneAssetsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-05-01 2021-05-01 0000899923 mygn:MyriadAutoimmuneAssetsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-07-01 2021-09-30 0000899923 mygn:MyriadRBMIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-05-21 2021-05-21 0000899923 mygn:MyriadRBMIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-07-01 2021-09-30 0000899923 mygn:MyriadRBMIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-09-30 0000899923 mygn:MyriadMyPathLLCLaboratoryMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-07-01 2021-09-30 0000899923 mygn:MyriadMyPathLLCLaboratoryMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-09-30 0000899923 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-07-01 2021-09-30 0000899923 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-09-30 0000899923 mygn:MyriadAutoimmuneAssetsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-09-30 0000899923 mygn:GatewayGenomicsLLCMember us-gaap:SubsequentEventMember 2022-11-01 2022-11-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________
FORM 10-Q
_________________________________________
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number: 0-26642
_________________________________________
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
_________________________________________
Delaware
(State or other jurisdiction
of incorporation or organization)
320 Wakara Way, Salt Lake City, UT
(Address of principal executive offices)
87-0494517
(I.R.S. Employer Identification No.)
84108
(Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
_________________________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.01 par value |  | MYGN |  | Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | x |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
|  |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
As of October 27, 2022, the registrant had 81,033,816 shares of $0.01 par value common stock outstanding.

MYRIAD GENETICS, INC.
INDEX TO FORM 10-Q

|  | Page
| PART I - Financial Information |
Item 1. | Financial Statements |
| Condensed Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021 | 4
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 (unaudited) | 5
| Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021 (unaudited) | 6
| Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021 (unaudited) | 7
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited) | 8
| Notes to Condensed Consolidated Financial Statements (unaudited) | 9
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 24
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 33
Item 4. | Controls and Procedures | 33
| PART II - Other Information |
Item 1. | Legal Proceedings | 35
Item 1A. | Risk Factors | 35
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 35
Item 3. | Defaults Upon Senior Securities | 35
Item 4. | Mine Safety Disclosures | 35
Item 5. | Other Information | 36
Item 6. | Exhibits | 36
| Signatures | 37

3

Table of Contents
MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in millions)

| September 30, 2022 |  | December 31, 2021
| (unaudited) |  |
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 110.7 |  |  | $ | 258.4 |
Marketable investment securities | 82.5 |  |  | 81.4 |
Trade accounts receivable | 102.2 |  |  | 91.3 |
Inventory | 19.6 |  |  | 15.3 |
Prepaid taxes | 17.8 |  |  | 18.4 |
Prepaid expenses and other current assets | 19.5 |  |  | 20.0 |
Total current assets | 352.3 |  |  | 484.8 |
Operating lease right-of-use assets | 110.6 |  |  | 81.8 |
Long-term marketable investment securities | 66.0 |  |  | 59.0 |
Property, plant, and equipment, net | 67.5 |  |  | 43.5 |
Intangibles, net | 370.8 |  |  | 404.1 |
Goodwill | 236.5 |  |  | 239.2 |
Other assets | 8.3 |  |  | 8.3 |
Total assets | $ | 1,212.0 |  |  | $ | 1,320.7 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 29.6 |  |  | $ | 29.6 |
Accrued liabilities | 85.3 |  |  | 156.5 |
Current maturities of operating lease liabilities | 14.0 |  |  | 13.0 |
Deferred revenues | 0.2 |  |  | 5.2 |
Total current liabilities | 129.1 |  |  | 204.3 |
Unrecognized tax benefits | 27.9 |  |  | 27.9 |
Long-term deferred taxes | 10.5 |  |  | 35.8 |
Noncurrent operating lease liabilities | 123.3 |  |  | 79.3 |
Other long-term liabilities | 4.6 |  |  | 5.6 |
Total liabilities | 295.4 |  |  | 352.9 |
Commitments and contingencies |  |  |
Stockholders’ equity: |  |  |
Common stock, 80.9 million and 80.0 million shares outstanding at September 30, 2022 and December 31, 2021, respectively | 0.8 |  |  | 0.8 |
Additional paid-in capital | 1,251.0 |  |  | 1,226.3 |
Accumulated other comprehensive loss | (11.3) |  |  | (5.1) |
Accumulated deficit | (323.9) |  |  | (254.2) |
Total Myriad Genetics, Inc. stockholders’ equity | 916.6 |  |  | 967.8 |
Non-controlling interest | — |  |  | — |
Total stockholders' equity | 916.6 |  |  | 967.8 |
Total liabilities and stockholders’ equity | $ | 1,212.0 |  |  | $ | 1,320.7 |

See accompanying notes to Condensed Consolidated Financial Statements.
4

Table of Contents
MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (unaudited)
(in millions, except per share amounts)

| Three months ended September 30, |  | Nine months ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenues: |  |  |  |  |  |  |
Molecular diagnostic testing | $ | 156.4 |  |  | $ | 167.3 |  |  | $ | 500.6 |  |  | $ | 505.6 |
Pharmaceutical and clinical services | — |  |  | — |  |  | — |  |  | 24.2 |
Total revenue | 156.4 |  |  | 167.3 |  |  | 500.6 |  |  | 529.8 |
Costs and expenses: |  |  |  |  |  |  |
Cost of molecular diagnostic testing | 50.4 |  |  | 47.8 |  |  | 148.1 |  |  | 139.9 |
Cost of pharmaceutical and clinical services | — |  |  | — |  |  | — |  |  | 11.9 |
Research and development expense | 20.5 |  |  | 18.8 |  |  | 62.0 |  |  | 61.4 |
Selling, general, and administrative expense | 130.5 |  |  | 180.6 |  |  | 368.2 |  |  | 462.2 |
Goodwill and long-lived asset impairment charges | — |  |  | — |  |  | 10.7 |  |  | 1.8 |
Total costs and expenses | 201.4 |  |  | 247.2 |  |  | 589.0 |  |  | 677.2 |
Operating loss | (45.0) |  |  | (79.9) |  |  | (88.4) |  |  | (147.4) |
Other income (expense): |  |  |  |  |  |  |
Interest income | 1.1 |  |  | 0.2 |  |  | 1.6 |  |  | 0.6 |
Interest expense | (0.8) |  |  | (1.1) |  |  | (2.3) |  |  | (6.1) |
Other | 0.5 |  |  | 120.6 |  |  | 0.6 |  |  | 139.3 |
Total other income (expense), net | 0.8 |  |  | 119.7 |  |  | (0.1) |  |  | 133.8 |
Income (loss) before income tax | (44.2) |  |  | 39.8 |  |  | (88.5) |  |  | (13.6) |
Income tax expense (benefit) | (9.1) |  |  | 15.2 |  |  | (18.8) |  |  | 6.0 |
Net income (loss) | (35.1) |  |  | 24.6 |  |  | (69.7) |  |  | (19.6) |
Net income (loss) attributable to non-controlling interest | — |  |  | — |  |  | — |  |  | — |
Net income (loss) attributable to Myriad Genetics, Inc. stockholders | $ | (35.1) |  |  | $ | 24.6 |  |  | $ | (69.7) |  |  | $ | (19.6) |
Net income (loss) per share: |  |  |  |  |  |  |
Basic | $ | (0.43) |  |  | $ | 0.31 |  |  | $ | (0.87) |  |  | $ | (0.25) |
Diluted | $ | (0.43) |  |  | $ | 0.30 |  |  | $ | (0.87) |  |  | $ | (0.25) |
Weighted average shares outstanding: |  |  |  |  |  |  |
Basic | 80.7 |  |  | 78.8 |  |  | 80.4 |  |  | 77.3 |
Diluted | 80.7 |  |  | 81.5 |  |  | 80.4 |  |  | 77.3 |

See accompanying notes to Condensed Consolidated Financial Statements.
5

Table of Contents
MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)
(in millions)

| Three months ended September 30, |  | Nine months ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Net income (loss) attributable to Myriad Genetics, Inc. stockholders | $ | (35.1) |  |  | $ | 24.6 |  |  | $ | (69.7) |  |  | $ | (19.6) |
Unrealized loss on available-for-sale debt securities, net of tax | (0.9) |  |  | (0.2) |  |  | (3.0) |  |  | (0.5) |
Change in foreign currency translation adjustment, net of tax | (1.5) |  |  | (0.2) |  |  | (3.2) |  |  | (1.6) |
Comprehensive income (loss) | (37.5) |  |  | 24.2 |  |  | (75.9) |  |  | (21.7) |
Comprehensive income (loss) attributable to Myriad Genetics, Inc. stockholders | $ | (37.5) |  |  | $ | 24.2 |  |  | $ | (75.9) |  |  | $ | (21.7) |

See accompanying notes to Condensed Consolidated Financial Statements.
6

Table of Contents
MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
(in millions)

| Common stock |  | Additional paid-in capital |  | Accumulated other comprehensive loss |  | Accumulated deficit |  | Non-controlling interest |  |  |  | Myriad Genetics, Inc. Stockholders’ equity
BALANCES AT DECEMBER 31, 2020 | $ | 0.8 |  |  | $ | 1,109.5 |  |  | $ | (2.3) |  |  | $ | (227.0) |  |  | $ | — |  |  |  |  | $ | 881.0 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | 26.0 |  |  | — |  |  | — |  |  | — |  |  |  |  | 26.0 |
Stock-based payment expense | — |  |  | 9.0 |  |  | — |  |  | — |  |  | — |  |  |  |  | 9.0 |
Net loss | — |  |  | — |  |  | — |  |  | (39.5) |  |  | — |  |  |  |  | (39.5) |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (1.3) |  |  | — |  |  | — |  |  |  |  | (1.3) |
BALANCES AT MARCH 31, 2021 | $ | 0.8 |  |  | $ | 1,144.5 |  |  | $ | (3.6) |  |  | $ | (266.5) |  |  | $ | — |  |  |  |  | $ | 875.2 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | 23.5 |  |  | — |  |  | — |  |  | — |  |  |  |  | 23.5 |
Stock-based payment expense | — |  |  | 8.9 |  |  | — |  |  | — |  |  | — |  |  |  |  | 8.9 |
Non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | (0.1) |  |  |  |  | (0.1) |
Net loss | — |  |  | — |  |  | — |  |  | (4.7) |  |  | — |  |  |  |  | (4.7) |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (0.4) |  |  | — |  |  | — |  |  |  |  | (0.4) |
BALANCES AT JUNE 30, 2021 | $ | 0.8 |  |  | $ | 1,176.9 |  |  | $ | (4.0) |  |  | $ | (271.2) |  |  | $ | (0.1) |  |  |  |  | $ | 902.4 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | 31.9 |  |  | — |  |  | — |  |  | — |  |  |  |  | 31.9 |
Stock-based payment expense | — |  |  | 10.0 |  |  | — |  |  | — |  |  | — |  |  |  |  | 10.0 |
Net income | — |  |  | — |  |  | — |  |  | 24.6 |  |  | — |  |  |  |  | 24.6 |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (0.4) |  |  | — |  |  | — |  |  |  |  | (0.4) |
BALANCES AT SEPTEMBER 30, 2021 | $ | 0.8 |  |  | $ | 1,218.8 |  |  | $ | (4.4) |  |  | $ | (246.6) |  |  | $ | (0.1) |  |  |  |  | $ | 968.5 |
BALANCES AT DECEMBER 31, 2021 | $ | 0.8 |  |  | $ | 1,226.3 |  |  | $ | (5.1) |  |  | $ | (254.2) |  |  | $ | — |  |  |  |  | $ | 967.8 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | (4.8) |  |  | — |  |  | — |  |  | — |  |  |  |  | (4.8) |
Stock-based payment expense | — |  |  | 10.1 |  |  | — |  |  | — |  |  | — |  |  |  |  | 10.1 |
Net loss | — |  |  | — |  |  | — |  |  | (20.5) |  |  | — |  |  |  |  | (20.5) |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (2.5) |  |  | — |  |  | — |  |  |  |  | (2.5) |
BALANCES AT MARCH 31, 2022 | $ | 0.8 |  |  | $ | 1,231.6 |  |  | $ | (7.6) |  |  | $ | (274.7) |  |  | $ | — |  |  |  |  | $ | 950.1 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | 2.3 |  |  | — |  |  | — |  |  | — |  |  |  |  | 2.3 |
Stock-based payment expense | — |  |  | 10.4 |  |  | — |  |  | — |  |  | — |  |  |  |  | 10.4 |
Net loss | — |  |  | — |  |  | — |  |  | (14.1) |  |  | — |  |  |  |  | (14.1) |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (1.3) |  |  | — |  |  | — |  |  |  |  | (1.3) |
BALANCES AT JUNE 30, 2022 | $ | 0.8 |  |  | $ | 1,244.3 |  |  | $ | (8.9) |  |  | $ | (288.8) |  |  | $ | — |  |  |  |  | $ | 947.4 |
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — |  |  | (2.7) |  |  | — |  |  | — |  |  | — |  |  |  |  | (2.7) |
Stock-based payment expense | — |  |  | 9.4 |  |  | — |  |  | — |  |  | — |  |  |  |  | 9.4 |
Net loss | — |  |  | — |  |  | — |  |  | (35.1) |  |  | — |  |  |  |  | (35.1) |
Other comprehensive loss, net of tax | — |  |  | — |  |  | (2.4) |  |  | — |  |  | — |  |  |  |  | (2.4) |
BALANCES AT SEPTEMBER 30, 2022 | $ | 0.8 |  |  | $ | 1,251.0 |  |  | $ | (11.3) |  |  | $ | (323.9) |  |  | $ | — |  |  |  |  | $ | 916.6 |

See accompanying notes to Condensed Consolidated Financial Statements.
7

Table of Contents
MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)

| Nine months ended September 30,
| 2022 |  | 2021
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
Net loss attributable to Myriad Genetics, Inc. stockholders | $ | (69.7) |  |  | $ | (19.6) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |  |  |
Depreciation and amortization | 39.0 |  |  | 49.5 |
Non-cash interest expense | 1.1 |  |  | 1.3 |
Non-cash lease expense | 8.6 |  |  | 9.8 |
Tenant improvement allowance received | 8.6 |  |  | — |
Stock-based compensation expense | 29.9 |  |  | 27.9 |
Deferred income taxes | (22.0) |  |  | (27.8) |
Unrecognized tax benefits | 0.1 |  |  | 1.5 |
Bad debt expense | 1.3 |  |  | 0.2 |
Loss on inventory | — |  |  | 6.5 |
Impairment of goodwill and long-lived assets | 10.7 |  |  | 1.8 |
Gain on sale of assets | — |  |  | (162.0) |
Changes in assets and liabilities: |  |  |
Prepaid expenses and other current assets | 0.4 |  |  | (6.7) |
Trade accounts receivable | (12.8) |  |  | (11.8) |
Inventory | (4.4) |  |  | (1.6) |
Prepaid taxes | 0.5 |  |  | 108.0 |
Other assets | (0.5) |  |  | (3.6) |
Accounts payable | (1.1) |  |  | (4.8) |
Accrued expenses and other liabilities | (83.4) |  |  | 79.9 |
Deferred revenues | (4.9) |  |  | (20.4) |
Net cash provided by (used in) operating activities | (98.6) |  |  | 28.1 |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
Capital expenditures | (30.7) |  |  | (14.6) |
Proceeds from sale of assets | — |  |  | 379.1 |
Purchases of marketable investment securities | (98.8) |  |  | (101.0) |
Proceeds from maturities and sales of marketable investment securities | 87.6 |  |  | 36.8 |
Net cash provided by (used in) investing activities | (41.9) |  |  | 300.3 |
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
Proceeds from common stock issued under stock-based compensation plans | 3.9 |  |  | 90.0 |
Payment of tax withheld for common stock issued under stock-based compensation plans | (9.1) |  |  | (8.6) |
Payment of contingent consideration recognized at acquisition | — |  |  | (3.3) |
Fees associated with refinancing of revolving credit facility | (0.7) |  |  | (1.2) |
Repayment of revolving credit facility | — |  |  | (226.4) |
Net cash used in financing activities | (5.9) |  |  | (149.5) |
Effect of foreign exchange rates on cash and cash equivalents | (1.3) |  |  | (0.7) |
Net increase (decrease) in cash and cash equivalents | (147.7) |  |  | 178.2 |
Cash and cash equivalents at beginning of the period | 258.4 |  |  | 117.0 |
Cash and cash equivalents at end of the period | $ | 110.7 |  |  | $ | 295.2 |

See accompanying notes to Condensed Consolidated Financial Statements.
8

Table of Contents
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1.BASIS OF PRESENTATION
Myriad Genetics, Inc. and its subsidiaries (collectively, the “Company” or “Myriad”) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment. The Company’s principal executive office is located in Salt Lake City, Utah.
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September 30, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30. The quarter ended December 31 is generally strong as the Company typically experiences an increase in volumes from patients who have met their annual insurance deductible. In the quarters ended March 31, the Company has typically experienced a decrease in volumes due to the annual reset of patient deductibles.
Due to the COVID-19 global pandemic, including variants of COVID-19 (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2021 and early 2022 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce.
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.
9

Table of Contents
2.REVENUE
Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are primarily derived from the following categories of products: Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.
The following table presents detail regarding the composition of the Company’s total revenue by type and by U.S. versus rest of world (“RoW”):

| Three months ended September 30,
| 2022 |  |  | 2021
(in millions) | U.S. |  | RoW |  | Total |  |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 60.2 |  |  | $ | 10.3 |  |  | $ | 70.5 |  |  |  | $ | 68.2 |  |  | $ | 11.2 |  |  | $ | 79.4 |
Tumor Profiling | 20.2 |  |  | 10.6 |  |  | 30.8 |  |  |  | 21.3 |  |  | 11.6 |  |  | 32.9 |
Prenatal | 21.9 |  |  | 0.2 |  |  | 22.1 |  |  |  | 23.5 |  |  | 0.1 |  |  | 23.6 |
Pharmacogenomics | 33.0 |  |  | — |  |  | 33.0 |  |  |  | 24.1 |  |  | — |  |  | 24.1 |
Autoimmune | — |  |  | — |  |  | — |  |  |  | 7.3 |  |  | — |  |  | 7.3 |
Total molecular diagnostic revenue | 135.3 |  |  | 21.1 |  |  | 156.4 |  |  |  | 144.4 |  |  | 22.9 |  |  | 167.3 |
Total revenue | $ | 135.3 |  |  | $ | 21.1 |  |  | $ | 156.4 |  |  |  | $ | 144.4 |  |  | $ | 22.9 |  |  | $ | 167.3 |
| Nine months ended September 30,
| 2022 |  |  | 2021
(in millions) | U.S. |  | RoW |  | Total |  |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 190.6 |  |  | $ | 30.0 |  |  | $ | 220.6 |  |  |  | $ | 207.1 |  |  | $ | 34.4 |  |  | $ | 241.5 |
Tumor Profiling | 61.4 |  |  | 35.5 |  |  | 96.9 |  |  |  | 63.4 |  |  | 31.0 |  |  | 94.4 |
Prenatal | 86.7 |  |  | 0.6 |  |  | 87.3 |  |  |  | 76.3 |  |  | 0.4 |  |  | 76.7 |
Pharmacogenomics | 95.5 |  |  | — |  |  | 95.5 |  |  |  | 64.3 |  |  | — |  |  | 64.3 |
Autoimmune | 0.3 |  |  | — |  |  | 0.3 |  |  |  | 28.2 |  |  | — |  |  | 28.2 |
Other | — |  |  | — |  |  | — |  |  |  | 0.5 |  |  | — |  |  | 0.5 |
Total molecular diagnostic revenue | 434.5 |  |  | 66.1 |  |  | 500.6 |  |  |  | 439.8 |  |  | 65.8 |  |  | 505.6 |
Pharmaceutical and clinical services revenue | — |  |  | — |  |  | — |  |  |  | 24.2 |  |  | — |  |  | 24.2 |
Total revenue | $ | 434.5 |  |  | $ | 66.1 |  |  | $ | 500.6 |  |  |  | $ | 464.0 |  |  | $ | 65.8 |  |  | $ | 529.8 |

10

Table of Contents
The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

| Nine months ended September 30,
(in millions) | 2022 |  |  | 2021
Deferred revenue - beginning balance | $ | 5.2 |  |  |  | $ | 32.7 |
Revenue recognized | (5.3) |  |  |  | (30.3) |
Prepayments | 0.3 |  |  |  | 10.1 |
Held for sale reclassification | — |  |  |  | (1.0) |
Deferred revenue - ending balance | $ | 0.2 |  |  |  | $ | 11.5 |

In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date.
In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices.
The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Cash collections for certain diagnostic tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and nine months ended September 30, 2022, the Company recognized $(5.3) million and $20.1 million in revenue, respectively, which resulted in a $(0.05) and $0.19 impact to earnings per share, respectively, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price.
The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.
11

Table of Contents
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, which represents greater than 10% of its revenues. Revenues received from Medicare represented 15% and 14% of total revenue for the three and nine months ended September 30, 2022, respectively, and 17% of total revenue for each of the three and nine months ended September 30, 2021. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at September 30, 2022 or December 31, 2021. The Company does not require collateral from its customers.
3.MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September 30, 2022 and December 31, 2021 were as follows:

(in millions) | Amortized cost |  | Gross unrealized holding gains |  | Gross unrealized holding losses |  | Estimated fair value
September 30, 2022 |  |  |  |  |  |  |
Cash and cash equivalents: |  |  |  |  |  |  |
Cash | $ | 57.8 |  |  | $ | — |  |  | $ | — |  |  | $ | 57.8 |
Cash equivalents | 52.9 |  |  | — |  |  | — |  |  | 52.9 |
Total cash and cash equivalents | 110.7 |  |  | — |  |  | — |  |  | 110.7 |
Available-for-sale: |  |  |  |  |  |  |
Corporate bonds and notes | 82.2 |  |  | — |  |  | (1.9) |  |  | 80.3 |
Municipal bonds | 23.9 |  |  | — |  |  | (0.4) |  |  | 23.5 |
Federal agency issues | 23.8 |  |  | — |  |  | (0.7) |  |  | 23.1 |
U.S. government securities | 21.8 |  |  | — |  |  | (0.2) |  |  | 21.6 |
Total | $ | 262.4 |  |  | $ | — |  |  | $ | (3.2) |  |  | $ | 259.2 |

(in millions) | Amortized cost |  | Gross unrealized holding gains |  | Gross unrealized holding losses |  | Estimated fair value
December 31, 2021 |  |  |  |  |  |  |
Cash and cash equivalents: |  |  |  |  |  |  |
Cash | $ | 195.2 |  |  | $ | — |  |  | $ | — |  |  | $ | 195.2 |
Cash equivalents | 63.2 |  |  | — |  |  | — |  |  | 63.2 |
Total cash and cash equivalents | 258.4 |  |  | — |  |  | — |  |  | 258.4 |
Available-for-sale: |  |  |  |  |  |  |
Corporate bonds and notes | 105.7 |  |  | 0.1 |  |  | (0.2) |  |  | 105.6 |
Municipal bonds | 16.1 |  |  | — |  |  | — |  |  | 16.1 |
Federal agency issues | 6.8 |  |  | — |  |  | — |  |  | 6.8 |
U.S. government securities | 11.9 |  |  | — |  |  | — |  |  | 11.9 |
Total | $ | 398.9 |  |  | $ | 0.1 |  |  | $ | (0.2) |  |  | $ | 398.8 |

12

Table of Contents
Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September 30, 2022:

(in millions) | Amortized cost |  | Estimated fair value
Cash | $ | 57.8 |  |  | $ | 57.8 |
Cash equivalents | 52.9 |  |  | 52.9 |
Available-for-sale: |  |  |
Due within one year | 83.4 |  |  | 82.5 |
Due after one year through five years | 68.3 |  |  | 66.0 |
Due after five years | — |  |  | — |
Total | $ | 262.4 |  |  | $ | 259.2 |

Additional information relating to fair value of marketable investment securities can be found in Note 4.
4.FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 12.75 years, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.
13

Table of Contents
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:

(in millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
September 30, 2022 |  |  |  |  |  |  |
Money market funds (a) | $ | 52.9 |  |  | $ | — |  |  | $ | — |  |  | $ | 52.9 |
Corporate bonds and notes | — |  |  | 80.3 |  |  | — |  |  | 80.3 |
Municipal bonds | — |  |  | 23.5 |  |  | — |  |  | 23.5 |
Federal agency issues | — |  |  | 23.1 |  |  | — |  |  | 23.1 |
U.S. government securities | — |  |  | 21.6 |  |  | — |  |  | 21.6 |
Contingent consideration | — |  |  | — |  |  | (7.2) |  |  | (7.2) |
Total | $ | 52.9 |  |  | $ | 148.5 |  |  | $ | (7.2) |  |  | $ | 194.2 |

(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

(in millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
December 31, 2021 |  |  |  |  |  |  |
Money market funds (a) | $ | 63.2 |  |  | $ | — |  |  | $ | — |  |  | $ | 63.2 |
Corporate bonds and notes | — |  |  | 105.6 |  |  | — |  |  | 105.6 |
Municipal bonds | — |  |  | 16.1 |  |  | — |  |  | 16.1 |
Federal agency issues | — |  |  | 6.8 |  |  | — |  |  | 6.8 |
U.S. government securities | — |  |  | 11.9 |  |  | — |  |  | 11.9 |
Contingent consideration | — |  |  | — |  |  | (8.6) |  |  | (8.6) |
Total | $ | 63.2 |  |  | $ | 140.4 |  |  | $ | (8.6) |  |  | $ | 195.0 |

(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
The following table reconciles the change in the fair value of the contingent consideration during the periods presented:

(in millions) | Carrying Amount
Balance December 31, 2021 | $ | 8.6 |
Change in fair value recognized in the Statement of Operations | (0.2) |
Translation adjustments recognized in Other comprehensive income (loss) | (1.2) |
Ending balance September 30, 2022 | $ | 7.2 |

5.PROPERTY, PLANT AND EQUIPMENT, NET

(in millions) | September 30, 2022 |  |  | December 31, 2021
Leasehold improvements | $ | 55.5 |  |  |  | $ | 38.0 |
Equipment | 120.5 |  |  |  | 112.4 |
Property, plant and equipment, gross | 176.0 |  |  |  | 150.4 |
Less accumulated depreciation | (108.5) |  |  |  | (106.9) |
Property, plant and equipment, net | $ | 67.5 |  |  |  | $ | 43.5 |

During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.

| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  | 2021
Depreciation expense | $ | 2.9 |  |  |  | $ | 2.6 |  |  | $ | 8.5 |  |  | $ | 8.9 |

14

Table of Contents
6.GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September 30, 2022:

(in millions) | Total
Beginning balance | $ | 239.2 |
Translation adjustments | (2.7) |
Ending balance | $ | 236.5 |

Intangible Assets
Intangible assets consists of purchased licenses and technologies. The following summarizes the amounts reported as intangible assets:

(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Net
At September 30, 2022 |  |  |  |  |
Purchased licenses and technologies | $ | 612.4 |  |  | $ | (241.6) |  |  | $ | 370.8 |
Total intangible assets | $ | 612.4 |  |  | $ | (241.6) |  |  | $ | 370.8 |

(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Net
At December 31, 2021 |  |  |  |  |
Purchased licenses and technologies | $ | 616.6 |  |  | $ | (212.5) |  |  | $ | 404.1 |
Total intangible assets | $ | 616.6 |  |  | $ | (212.5) |  |  | $ | 404.1 |

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  |  | 2021
Amortization of intangible assets | $ | 10.2 |  |  |  | $ | 11.6 |  |  | $ | 30.5 |  |  |  | $ | 40.6 |

7.ACCRUED LIABILITIES

(in millions) | September 30, 2022 |  |  | December 31, 2021
Employee compensation and benefits | $ | 42.6 |  |  |  | $ | 52.8 |
Legal charges pending settlement | — |  |  |  | 62.0 |
Accrued taxes payable | 3.8 |  |  |  | 4.0 |
Refunds payable and reserves | 11.0 |  |  |  | 9.8 |
Short-term contingent consideration | 2.7 |  |  |  | 3.2 |
Accrued royalties | 4.7 |  |  |  | 5.4 |
Other accrued liabilities | 20.5 |  |  |  | 19.3 |
Total accrued liabilities | $ | 85.3 |  |  |  | $ | 156.5 |

15

Table of Contents
8.LONG-TERM DEBT
On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 (the "Maturity Date") and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company’s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (as modified, the “Modification Period”). This included a modification to the Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revision to certain negative covenants of the Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 to the Facility, which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0 million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $150.0 million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $350.0 million to $300.0 million, with a further reduction in the maximum aggregate principal commitment from $300.0 million to $250.0 million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. On July 26, 2022, the Company entered into Amendment No. 4 to the Facility (the "Amended Facility"), which extended the Modification Period through the Maturity Date, decreased the maximum aggregate principal commitment from $250.0 million to $200.0 million, with a further reduction to $150.0 million by December 31, 2022, waived compliance with the leverage ratio and interest coverage ratio covenants through the Maturity Date, and provided for monthly reporting of the Company's liquidity if the total revolving credit exposure is greater than $0, without giving effect to the dollar amount of any letter of credit exposure not in excess of $5.0 million.
Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to stockholders.
The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. Amendment No. 4 replaced the option to make Eurodollar borrowings, which bore interest by reference to the LIBOR rate, with term benchmark loans, which will bear interest by reference to the secured overnight financing rate ("SOFR"). Amendment No. 4 did not modify the applicable margins and undrawn fee amounts. The interest rate for term benchmark loans continues to be fixed at a spread of SOFR plus 350 basis points on drawn balances and undrawn fees continue to be 50 basis points. The SOFR floor was revised to 0.0%.
During the year ended December 31, 2021, the Company made principal repayments totaling $226.4 million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of September 30, 2022 and December 31, 2021.
9.OTHER LONG-TERM LIABILITIES

(in millions) | September 30, 2022 |  |  | December 31, 2021
Contingent consideration | $ | 4.5 |  |  |  | $ | 5.4 |
Other | 0.1 |  |  |  | 0.2 |
Total other long-term liabilities | $ | 4.6 |  |  |  | $ | 5.6 |

The Company's balance of other long-term liabilities at September 30, 2022 and December 31, 2021 consisted primarily of the long-term portion of contingent consideration related to the acquisition of Sividon Diagnostics.
16

Table of Contents
10.PREFERRED AND COMMON STOCKHOLDERS' EQUITY
The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at September 30, 2022.
The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.9 million shares of common stock issued and outstanding at September 30, 2022.
Common stock issued and outstanding

| Nine months ended September 30,
(in millions) | 2022 |  |  | 2021
Beginning common stock issued and outstanding | 80.0 |  |  |  | 75.4 |
Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan | 0.9 |  |  |  | 4.3 |
Common stock issued and outstanding at end of period | 80.9 |  |  |  | 79.7 |

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.
The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:

| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  |  | 2021
Denominator: |  |  |  |  |  |  |  |  |
Weighted-average shares outstanding used to compute basic EPS | 80.7 |  |  |  | 78.8 |  |  | 80.4 |  |  |  | 77.3 |
Effect of dilutive shares | — |  |  |  | 2.7 |  |  | — |  |  |  | — |
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS | 80.7 |  |  |  | 81.5 |  |  | 80.4 |  |  |  | 77.3 |

Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:

| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  |  | 2021
Anti-dilutive options and RSUs excluded from EPS computation | 4.5 |  |  |  | 0.1 |  |  | 4.5 |  |  |  | 4.9 |

Stock Repurchase Program
In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 million of the Company’s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of September 30, 2022, the Company has $110.7 million remaining under its current share repurchase authorization. No shares were repurchased during the nine months ended September 30, 2022 or 2021.
17

Table of Contents
11.STOCK-BASED COMPENSATION
On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of September 30, 2022, the Company has 2.0 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan.
The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years or after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. Options and RSUs granted to non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date.
The performance and market conditions associated with PSU awards granted during the nine months ended September 30, 2022 include vesting that is based on revenue growth targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the PSUs is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. The portion of the awards pertaining to relative total stockholder return represent market based awards and, accordingly, the estimated fair value of such awards are recognized over the performance period. We have also assessed that as of September 30, 2022 the performance conditions for the remaining two performance targets (revenue growth and adjusted earnings per share) are considered probable of being achieved and, accordingly, these portions of the awards are also being expensed over the performance period.
Stock Options
A summary of the stock option activity under the Company’s equity plans and inducement awards for the nine months ended September 30, 2022 is as follows:

(number of shares in millions) | Number of Shares |  | Weighted Average Exercise Price
Options outstanding at December 31, 2021 | 1.4 |  |  | $ | 20.36 |
Less: |  |  |
Options exercised | — |  |  | $ | 26.22 |
Options canceled or expired | (0.6) |  |  | $ | 26.85 |
Options outstanding at September 30, 2022 | 0.8 |  |  | $ | 15.62 |
Options exercisable at September 30, 2022 | 0.5 |  |  | $ | 16.99 |

As of September 30, 2022, there was $1.4 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.2 years. There were no options granted during the nine months ended September 30, 2022.
18

Table of Contents
Restricted Stock Units
A summary of the RSU awards activity under the Company’s equity plans and inducement awards, including PSU awards, for the nine months ended September 30, 2022 is as follows:

(number of shares in millions) | Number of Shares |  | Weighted Average Grant Date Fair Value
RSUs outstanding at December 31, 2021 | 3.1 |  |  | $ | 24.96 |
RSUs granted | 1.9 |  |  | $ | 26.09 |
Less: |  |  |
RSUs vested | (1.0) |  |  | $ | 27.27 |
RSUs canceled | (0.3) |  |  | $ | 26.57 |
RSUs outstanding at September 30, 2022 | 3.7 |  |  | $ | 24.75 |

As of September 30, 2022, there was $70.8 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.4 years.
Employee Stock Purchase Plan
The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012, under which 2.0 million shares of common stock were originally authorized. On September 23, 2021, the Board of Directors of the Company approved an Amended and Restated 2012 Employee Stock Purchase Plan (the "Amended and Restated Purchase Plan"), which authorized an additional 2.0 million shares of common stock and extended the term of the plan to November 30, 2032, subject in each case to obtaining stockholder approval. The Company's stockholders subsequently approved the Amended and Restated Purchase Plan on June 2, 2022. The Amended and Restated Purchase Plan also expanded the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capped the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the Amended and Restated Purchase Plan twice yearly at the end of each offering period. As of September 30, 2022, 1.8 million shares of common stock were available for issuance under the Amended and Restated Purchase Plan.
Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:

| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  |  | 2021
Cost of molecular diagnostic testing | $ | 0.5 |  |  |  | $ | 0.4 |  |  | $ | 1.3 |  |  |  | $ | 1.1 |
Cost of pharmaceutical and clinical services | — |  |  |  | — |  |  | — |  |  |  | 0.1 |
Research and development expense | 1.0 |  |  |  | 0.8 |  |  | 4.4 |  |  |  | 3.3 |
Selling, general, and administrative expense | 7.9 |  |  |  | 8.8 |  |  | 24.2 |  |  |  | 23.4 |
Total stock-based compensation expense | $ | 9.4 |  |  |  | $ | 10.0 |  |  | $ | 29.9 |  |  |  | $ | 27.9 |

12.INCOME TAXES
In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.
19

Table of Contents
Income tax benefit for the three months ended September 30, 2022 was $9.1 million, or approximately 20.6% of pre-tax loss compared to an income tax expense of $15.2 million, or approximately 38.2% of pre-tax loss, for the three months ended September 30, 2021. Income tax benefit for the nine months ended September 30, 2022 was $18.8 million, or approximately 21.2% of pre-tax loss compared to an income tax expense of $6.0 million, or approximately (44.1)% of pre-tax loss, for the nine months ended September 30, 2021. For the three and nine months ended September 30, 2022, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation, stock compensation, uncertain tax positions and asset impairments. For the three and nine months ended September 30, 2021, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation, stock compensation, carrying back net operating losses, asset impairments, release of a valuation allowance, and differences between the book and tax basis of assets divested. In connection with the sale of Crescendo Biosciences, the Company recognized a change in the valuation allowance related to the change of the corresponding tax attributes, with no impact on the Company's income tax expense in the quarter ended September 30, 2022.
The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the State of California for the fiscal years ended June 30, 2017-2018, the State of New Jersey for the fiscal years ended June 30, 2013-2017; and Switzerland for the fiscal years ended June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.
13.COMMITMENTS AND CONTINGENCIES
Legal Proceedings
The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amount of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company is involved, and has received subpoenas, from time to time, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.
The Company intends to vigorously defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.
The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability.
As of September 30, 2022, the Company has not recorded any accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company’s insurance, or if the Company’s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company’s results of operations, financial condition or cash flows.
20

Table of Contents
Securities Class Action
On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (the “Defendants”). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned In re Myriad Genetics, Inc. Securities Litigation (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions. The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss. On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. The parties currently are engaged in discovery.
Stockholder Derivative Actions
On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit.
On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action.
On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action.
On September 17, 2021, a stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit.
Other Legal Matters
On December 21, 2020, Ravgen, Inc. filed a lawsuit against the Company and its wholly owned subsidiary, Myriad Women's Health, Inc., in the United States District Court for the District of Delaware, alleging infringement of two Ravgen-owned patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, injunctive relief, and recovery of attorney's fees and costs. Various third parties have filed challenges to the validity of the asserted patents with the United States Patent and Trademark Office, which challenges have been instituted for review. On March 14, 2022, the case was stayed pending the outcome of the first of these validity challenges.
21

Table of Contents
On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit. On May 2, 2022, the plaintiff amended her complaint. On June 2, 2022, the Company filed a motion to dismiss the amended complaint. On July 26, 2022, the United States District Court in the Northern District of California granted and denied in part the Company's motion to dismiss the amended complaint. As part of the court's order, plaintiff was granted leave to file a second amended complaint. The plaintiff filed a second amended complaint on August 16, 2022. On September 6, 2022, the Company filed a motion to dismiss the second amended complaint.
From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.
14.SUPPLEMENTAL CASH FLOW INFORMATION

| Nine months ended September 30,
(in millions) | 2022 |  |  | 2021
Cash paid during the period for income taxes | $ | 1.6 |  |  |  | $ | 2.4 |
Cash paid for interest | — |  |  |  | 2.1 |
Cash received for income tax receivables | — |  |  |  | 89.9 |
Establishment of operating lease right-of-use assets and lease liabilities |  |  |  |
Operating lease right-of-use assets | $ | 46.1 |  |  |  | $ | 40.5 |
Operating lease liabilities | 46.1 |  |  |  | 46.8 |
Tenant improvement allowance not yet received | 17.8 |  |  |  | — |
Purchases of property, plant and equipment in accounts payable and accrued liabilities | 4.3 |  |  |  | — |

15.LEASES
The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to fifteen years. During the nine months ended September 30, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recorded an impairment charge on right-of-use assets of $8.6 million and an impairment charge of $2.1 million on the related leasehold improvements. The total $10.7 million impairment is included in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statement of Operations.
In the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. The Company will take possession of the leased facility in phases, which began in the three months ended June 30, 2022. As a result, the Company has recognized the related lease balances for the phase, or portion, of the leased facility that the Company has taken possession of, and will recognize the additional phases of the leased facility as possession occurs. As of September 30, 2022, the Company has recognized an approximately $13.9 million right-of-use asset and corresponding lease liability, net of tenant improvement allowance not yet received. Total future rent payments under the lease are approximately $77.8 million.
During the three months ended September 30, 2022, the Company took possession of a lease for approximately 63,000 square feet in South San Francisco, California with a term of 10 years, which, along with rent payments, are expected to commence in the third quarter of 2023. As a result, the Company recognized the related right-of-use asset and lease liability, net of tenant improvement allowance not yet received, of $30.7 million in the Condensed Consolidated Balance Sheet as of September 30, 2022. Total future rent payments under the lease are approximately $58.8 million.
22

Table of Contents
16.DIVESTITURES
On May 28, 2021, the Company completed its sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for total cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a net gain of $31.2 million in the quarter ended June 30, 2021, in Other income on the Company’s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company’s diagnostics reporting segment.
On May 1, 2021, the Company entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for total cash consideration of $150.0 million. The Autoimmune Business Transaction closed on September 13, 2021. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6 million in the quarter ended September 30, 2021, in Other income on the Company's Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad Autoimmune operations were included in the Company’s diagnostics reporting segment.
On May 21, 2021, the Company entered into a definitive agreement to sell Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $197.0 million. This transaction closed on July 1, 2021. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0 million in the quarter ended September 30, 2021, in Other income on the Company's Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad RBM, Inc. operations were included in the Company’s other reporting segment.
Inventory
In connection with the divestiture transactions, the Company recognized losses of $5.2 million and $6.5 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the nine months ended September 30, 2021, as the Company would no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021.
The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:

(in millions) | Three months ended September 30, 2021 |  |  | Nine months ended September 30, 2021
Gain on sale of Myriad RBM, Inc. | $ | 121.0 |  |  |  | $ | 121.0 |
Gain on sale of Myriad myPath, LLC laboratory | — |  |  |  | 31.2 |
Gain (loss) on inventory | 0.8 |  |  |  | (11.7) |
Loss on sale of Myriad Autoimmune assets | (0.6) |  |  |  | (0.6) |
Other | (0.6) |  |  |  | (0.6) |
Total other income | $ | 120.6 |  |  |  | $ | 139.3 |

17.SUBSEQUENT EVENTS
On November 1, 2022, the Company acquired Gateway Genomics, LLC ("Gateway"), a personal genomics company and developer of consumer genetic tests that gives families insight into their future children, for an upfront cash purchase price of $67.5 million, subject to customary adjustments, and up to $32.5 million in contingent cash consideration upon the achievement of certain performance-based targets. The acquisition was consummated pursuant to an Agreement and Plan of Merger, dated November 1, 2022, among the Company, Genos Merger Sub LLC, a wholly owned subsidiary of the Company ("Merger Sub"), Gateway, the equity holders of Gateway, and Shareholder Representative Services LLC, in its capacity as the equity holders' representative, whereby Merger Sub merged with and into Gateway, with Gateway surviving the merger as the surviving company and a wholly owned subsidiary of Myriad.
23

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Dollars and shares in millions, except per share data)
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on February 25, 2022. “We,” “us,” “our,” “Myriad” and the “Company” as used in this Quarterly Report on Form 10‑Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.
Cautionary Statement Regarding Forward-Looking Statements
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10‑Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes,” “seek,” “could,” “continue,” “likely,” “will,” “strategy” and “goal” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to:
•the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis;
•risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests;
•risks related to changes in governmental or private insurers’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests;
•risks related to increased competition and the development of new competing tests and services;
•uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services and on our ability to efficiently and flexibly manage our business;
•the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all;
•the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States;
•the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms;
•risks related to delays or other problems with operating and constructing our laboratory testing facilities;
•risks related to public concern over genetic testing in general or our tests in particular;
•risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems;
•risks related to our ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all;
•risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire, or develop;
•risks related to our projections about the potential market opportunity for our current and future products;
•the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests;
•the risk of patent-infringement claims or challenges to the validity of our patents;
•risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries;
•risks related to security breaches, loss of data and other disruptions, including from cyberattacks;
•risks of new, changing and competitive technologies and regulations in the United States and internationally;
•the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;
24

Table of Contents
•risks related to the material weakness related to our general information technology controls, including the impact thereof and our remediation plan, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting;
•risks related to current and future investigations, claims or lawsuits, including product or professional liability claims, and risks related to the amount of our insurance coverage limits and scope of insurance coverage with respect thereto; and
•other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2022.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report, or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. All forward-looking statements in this Quarterly Report attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
General
We are a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. We provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. We develop and offer genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower health care costs.
Personalized genetic data and digital and virtual consumer trends are converging to change traditional models of care. Significant growth opportunities exist to help patient populations with pressing health care needs through innovative solutions and services. We are currently executing a strategic transformation and growth plan that aims to capitalize on those trends by focusing on three strategic priorities: (1) innovation that improves clinical outcomes, ease of use, and access; (2) enterprise capabilities to accelerate growth and scale to market opportunity; and (3) a focus on execution and delivery of consistent results. In connection with these strategic priorities, we are focusing our efforts in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In each of these areas, we intend to develop and enhance best-in-class products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. By investing in tech-enabled commercial tools, we believe we will be able to drive increased engagement, improve revenue cycle management, and reduce complexity and cost. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability. With a foundation of financial, commercial, operational and technological strength, we expect to accelerate growth as we launch a new enterprise commercial model, launch a unified ordering portal, invest in new sequencing technologies, further develop direct-to-consumer channels, and build commercial capabilities to support new products and offerings.
Business Updates
During the quarter ended September 30, 2022, we continued to take meaningful steps to expand access to our products and execute upon our transformation plan. We also made the following recent announcements:
•On November 1, 2022, we announced the acquisition of Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests that gives families insight into their future children.
•On October 31, 2022, we announced the election of Paul Bisaro to the Company's Board of Directors, effectively immediately.
•On July 12, 2022, we announced that the Journal of the American Medical Association published study results that concluded Major Depressive Disorder remission rates were significantly improved when clinicians had access to GeneSight® Psychotropic test results from Myriad Genetics, Inc.
•On August 16, 2022, we announced two partnerships with the Institut für Hämopathologie Hamburg (HPH) in Hamburg, Germany and the Centre Georges-Francois LeClerc (CGFL) in Dijon, France to expand access to MyChoice® CDx Plus testing.
25

Table of Contents
•On August 25, 2022, we announced expanded coverage in Japan for the use of Myriad's BRACAnalysis® Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza®(olaparib).
•On August 31, 2022, we announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study that shows the EndoPredict® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer. This newly published study represented the first clinical validation of EndoPredict in a solely premenopausal population.
•Molecular Diagnostic Services Program (MolDX®) assigned the MyRisk® hereditary cancer test Current Procedural Terminology (CPT) code 81479. The Centers for Medicare & Medicaid Services (CMS) preliminarily determined to crosswalk GeneSight to Proprietary Laboratory Analyses (PLA) code 0175U.
Results of Operations for the Three Months Ended September 30, 2022 and 2021
The results of operations for the three months ended September 30, 2022 and 2021 are discussed below.
Revenue

| Three months ended September 30, |  | Change |  | % of total revenue
(in millions) | 2022 |  |  | 2021 |  | 2022 |  | 2022 |  | 2021
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 70.5 |  |  |  | $ | 79.4 |  |  | $ | (8.9) |  |  | 45% |  | 47%
Tumor Profiling | 30.8 |  |  |  | 32.9 |  |  | (2.1) |  |  | 20% |  | 20%
Prenatal | 22.1 |  |  |  | 23.6 |  |  | (1.5) |  |  | 14% |  | 14%
Pharmacogenomics | 33.0 |  |  |  | 24.1 |  |  | 8.9 |  |  | 21% |  | 14%
Autoimmune | — |  |  |  | 7.3 |  |  | (7.3) |  |  | —% |  | 4%
Total molecular diagnostic revenue | 156.4 |  |  |  | 167.3 |  |  | (10.9) |  |  |  |  |
Total revenue | $ | 156.4 |  |  |  | $ | 167.3 |  |  | $ | (10.9) |  |  | 100% |  | 100%

Molecular diagnostic revenues decreased $10.9 million for the three months ended September 30, 2022 compared to the same period in the prior year. Hereditary Cancer revenues decreased $8.9 million compared to the same period in the prior year due to a 15% decrease in average reimbursement per test, driven by change in the estimated reimbursement per test, changes in foreign exchange rates, and a change in customer mix. Autoimmune revenues decreased $7.3 million due to the sale of the Myriad Autoimmune business on September 13, 2021. Tumor profiling revenues decreased $2.1 million compared to the same period in the prior year due primarily to one-time milestone revenue earned in the three months ended September 30, 2021. Prenatal revenues decreased $1.5 million compared to the same period in the prior year due primarily to a decrease in the estimated reimbursement per test. Revenues from Pharmacogenomics increased $8.9 million compared to the same period in the prior year due primarily to a 34% increase in volume.
Cost of Sales

| Three months ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
Cost of molecular diagnostic testing | $ | 50.4 |  |  |  | $ | 47.8 |  |  | $ | 2.6
Cost of molecular diagnostic testing as a % of revenue | 32.2 | % |  |  | 28.6 | % |  |

The cost of molecular diagnostic testing as a percentage of revenue increased from 28.6% to 32.2% during the three months ended September 30, 2022 compared to the same period in the prior year. The increase was primarily driven by the shift in the product mix for the current period and an increase in compensation costs due to higher headcount.
26

Table of Contents
Research and Development Expense

| Three months ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
R&D expense | $ | 20.5 |  |  |  | $ | 18.8 |  |  | $ | 1.7
R&D expense as a % of total revenue | 13.1 | % |  |  | 11.2 | % |  |

Research and development expense for the three months ended September 30, 2022 increased compared to the same period in the prior year primarily due to an increase in headcount.
Selling, General and Administrative Expense

| Three months ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
Selling, general and administrative expense | $ | 130.5 |  |  |  | $ | 180.6 |  |  | $ | (50.1)
Selling, general and administrative expense as a % of total revenue | 83.4 | % |  |  | 107.9 | % |  |

Selling, general and administrative expense decreased for the three months ended September 30, 2022 compared to the same period in the prior year primarily due to a $51.2 million decrease in general legal expenses, due primarily to a $48.0 million legal accrual related to the Crescendo Bioscience, LLC qui tam lawsuit in the prior period, a $4.2 million decrease in bonus expense, and a $2.6 million decrease in costs incurred in the current period as part of the Company's strategic transformation initiatives, partially offset by a $3.0 million increase in sales and marketing expenses due to more in-person sales and marketing events and travel-related expenses in the current period. In addition, consulting expenses, computer and hardware expenses, and general compensation expenses increased in the current period.
Other Income (Expense), Net

| Three months ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
Other income (expense), net | $ | 0.8 |  |  |  | $ | 119.7 |  |  | $ | (118.9)

Other income (expense), net decreased for the three months ended September 30, 2022 compared to the same period in the prior year due primarily to the $121.0 million net gain recognized on the sale of Myriad RBM, Inc. in the prior period, partially offset by the $0.6 million net loss recognized on the sale of Myriad Autoimmune assets in the prior period. There were no similar items in the current period.
Income Tax Expense (Benefit)

| Three months ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
Income tax expense (benefit) | $ | (9.1) |  |  |  | $ | 15.2 |  |  | $ | (24.3)
Effective tax rate | 20.6 | % |  |  | 38.2 | % |  |

Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 4.2%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.
Income tax benefit for the three months ended September 30, 2022 was $9.1 million, and our effective tax rate was 20.6%. For the three months ended September 30, 2022, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation, uncertain tax positions, and stock compensation. For the three months ended September 30, 2021, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation, the tax impact of the CARES Act, differences between the book and tax basis of assets divested, and stock compensation.
27

Table of Contents
Results of Operations for the Nine Months Ended September 30, 2022 and 2021
The results of operations for the nine months ended September 30, 2022 and 2021 are discussed below.
Revenue

| Nine months ended September 30, |  | Change |  | % of Total Revenue
(in millions) | 2022 |  | 2021 |  | 2022 |  | 2022 |  | 2021
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 220.6 |  |  | $ | 241.5 |  |  | $ | (20.9) |  |  | 44% |  | 46%
Tumor Profiling | 96.9 |  |  | 94.4 |  |  | 2.5 |  |  | 19% |  | 18%
Prenatal | 87.3 |  |  | 76.7 |  |  | 10.6 |  |  | 17% |  | 14%
Pharmacogenomics | 95.5 |  |  | 64.3 |  |  | 31.2 |  |  | 19% |  | 12%
Autoimmune | 0.3 |  |  | 28.2 |  |  | (27.9) |  |  | —% |  | 5%
Other | — |  |  | 0.5 |  |  | (0.5) |  |  | —% |  | —%
Total molecular diagnostic revenue | 500.6 |  |  | 505.6 |  |  | (5.0) |  |  |  |  |
Pharmaceutical and clinical service revenue | — |  |  | 24.2 |  |  | (24.2) |  |  | —% |  | 5%
Total revenue | $ | 500.6 |  |  | $ | 529.8 |  |  | $ | (29.2) |  |  | 100% |  | 100%

Molecular diagnostic revenue for the nine months ended September 30, 2022 decreased $5.0 million compared to the same period in the prior year. Autoimmune revenues decreased $27.9 million due to the sale of the Myriad Autoimmune business on September 13, 2021. Hereditary Cancer revenues decreased $20.9 million compared to the same period in the prior year due primarily to a 4% decrease in volume and a 5% decrease in average reimbursement per test driven by changes in foreign exchange rates. These decreases in revenue were partially offset by increases across other products. Revenue from Pharmacogenomics increased $31.2 million compared to the same period in the prior year due primarily to a 40% increase in volume. Prenatal revenues increased $10.6 million compared to the same period in the prior year due primarily to a 15% increase in the average reimbursement per test. Tumor Profiling revenues increased $2.5 million compared to the same period in the prior year due to a 3% increase in volume and a shift in product mix, partially offset by a decrease in international revenue due to changes in foreign exchange rates and a one-time milestone revenue earned in the prior period.
Pharmaceutical and clinical service revenues were $24.2 million in the prior period. As a result of the sale of Myriad RBM, Inc. on July 1, 2021, there were no Pharmaceutical and clinical services revenues during the current period.
Cost of Sales

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
Cost of molecular diagnostic testing | $ | 148.1 |  |  | $ | 139.9 |  |  | $ | 8.2
Cost of molecular diagnostic testing as a % of revenue | 29.6 | % |  | 27.7 | % |  |
Cost of pharmaceutical and clinical services | $ | — |  |  | $ | 11.9 |  |  | $ | (11.9)
Cost of pharmaceutical and clinical services as a % of revenue | — | % |  | 49.2 | % |  |

The cost of molecular diagnostic testing as a percentage of revenue increased from 27.7% to 29.6% during the nine months ended September 30, 2022 compared to the same period in the prior year. The increase was primarily driven by the shift in the product mix for the current period and an increase in compensation costs due to an increase in the number of employees.
The cost of pharmaceutical and clinical services as a percentage of revenue was 49.2% for the nine months ended September 30, 2021. The sale of Myriad RBM, Inc. was completed on July 1, 2021, and as a result there were no corresponding costs during the current period.
28

Table of Contents
Research and Development Expense

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
R&D expense | $ | 62.0 |  |  | $ | 61.4 |  |  | $ | 0.6
R&D expense as a % of total revenue | 12.4 | % |  | 11.6 | % |  |

Research and development expense for the nine months ended September 30, 2022 increased compared to the same period in the prior year primarily due to an increase in compensation expense and computer hardware and software costs in the current period, partially offset by a decrease in clinical costs and costs incurred in the current period related to the Company’s strategic transformation initiatives as compared to the same period in the prior year.
Selling, General and Administrative Expense

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
Selling, general and administrative expense | $ | 368.2 |  |  | $ | 462.2 |  |  | $ | (94.0)
Selling, general and administrative expense as a % of total revenue | 73.6 | % |  | 87.2 | % |  |

Selling, general and administrative expense decreased for the nine months ended September 30, 2022 compared to the same period in the prior year primarily due to a $71.6 million decrease in legal expenses, which is primarily driven by a $48.0 million legal accrual related to the Crescendo Bioscience, LLC qui tam lawsuit in the prior period, a $14.0 million legal accrual related to the Abelli settlement in the prior period, and the receipt of $11.4 million from insurers to offset the previously accrued Abelli settlement and other legal expenses in the current period, a $16.8 million decrease in costs incurred in the current period as part of the Company's strategic transformation initiative, which is largely due to a decrease in retention and severance costs in the current period, a $15.3 million decrease in compensation-related expenses due primarily to a decrease in bonus and commission expenses, a $10.1 million decrease in amortization expense due to intangible assets sold in the divestitures in the prior year, partially offset by an $11.4 million increase in sales and marketing expenses due to more in-person sales and marketing events and travel-related expenses in the current period, a $3.6 million increase in consulting expenses, and a $2.5 million increase in computer and hardware expenses.
Goodwill and long-lived asset impairment charges

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
Goodwill and long-lived asset impairment charges | $ | 10.7 |  |  | $ | 1.8 |  |  | $ | 8.9
Goodwill and long-lived asset impairment charges as a % of total revenue | 2.1 | % |  | 0.3 | % |  |

Goodwill and long-lived asset impairment charges increased for the nine months ended September 30, 2022 compared to the same period in the prior year primarily due to the Company recognizing an $8.6 million impairment to right-of-use assets and a $2.1 million impairment to the related leasehold improvements in the current period as a result of its decision to no longer use one of its facilities in order to consolidate space. During the prior period, the Company recognized a $1.8 million impairment to right-of-use assets as a result of the voluntary early termination of certain lease agreements to consolidate space.
29

Table of Contents
Other Income (Expense), Net

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
Other income (expense), net | $ | (0.1) |  |  | $ | 133.8 |  |  | $ | (133.9)

Other income (expense), net decreased for the nine months ended September 30, 2022 compared to the same period in the prior year due primarily to the $121.0 million net gain recognized on the sale of Myriad RBM, Inc. and the $31.2 million net gain recognized on the sale of the Myriad myPath, LLC laboratory in the prior period, partially offset by charges in the prior period, including losses of $5.2 million and $6.5 million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with the divestiture transactions, as well as a $1.5 million decrease in interest expense in the current period. The interest expense in the prior period is related to the debt outstanding at that time with no corresponding debt outstanding in the current period, as the debt was repaid in full on July 30, 2021.
Income Tax Benefit

| Nine months ended September 30, |  |
(in millions) | 2022 |  | 2021 |  | Change
Income tax benefit | $ | (18.8) |  |  | $ | 6.0 |  |  | $ | (24.8)
Effective tax rate | 21.2 | % |  | (44.1) | % |  |

Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 4.2%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.
Income tax benefit for the nine months ended September 30, 2022 was $18.8 million, and our effective tax rate was 21.2%. For the nine months ended September 30, 2022, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, uncertain tax positions, stock compensation and asset impairments. For the nine months ended September 30, 2021, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation, differences between the book and tax basis of assets divested, the tax impact of the CARES Act, stock compensation, and release of a valuation allowance.
30

Table of Contents
Liquidity and Capital Resources
Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our expected future cash flows from operations, and, in certain circumstances, as discussed below, amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, technology and acquisitions. We believe that investing organically through research and development or acquisitively to support business strategy provides the best return on invested capital.
We believe that our existing capital resources will be sufficient to meet our projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments.
All previously outstanding borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from divestitures and as such, we have no outstanding borrowings as of September 30, 2022. Our available capital resources, however, may be consumed more rapidly than currently expected, or may be insufficient, and we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all, and the current rising interest rate environment could make any potential financing more difficult or expensive to obtain. In addition, we have a decreased borrowing limit and are subject to financial covenants under our Amended Facility, which could limit our ability to incur additional indebtedness or impact our decision to pursue other financing. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.
The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents and marketable securities totaled $259.2 million as of September 30, 2022. Our revolving commitment amount is $200.0 million as of July 26, 2022, with a further reduction to $150.0 million by December 31, 2022. As our total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0 million as of September 30, 2022, we are unable to make future borrowings unless related to a permitted acquisition. In addition, we are subject to a minimum liquidity covenant, which requires us to maintain liquidity—defined as the sum of our unrestricted cash, cash equivalents and marketable investment securities plus the aggregate undrawn and available amount of the revolving commitments—of $150.0 million.
From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods. In February 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, is expected to commence in the third quarter of 2023. Total future rent payments under the lease is approximately $77.8 million. In December 2021, we entered into a non-cancelable operating lease for approximately 63,000 square feet in South San Francisco, California, which, along with rent payments, is expected to commence in the third quarter of 2023. Total future rent payments under the lease are approximately $58.8 million. In addition, in April 2022, we paid $48.0 million for the settlement of the qui tam lawsuit against Crescendo Bioscience, LLC and the Company.
Due to the continually evolving global situation from the COVID-19 pandemic, it is not possible to predict whether ongoing consequences of the pandemic are reasonably likely to materially affect our liquidity and capital resources in the future. Because of the technical nature of our business and our focus on science, research and development, we are highly dependent upon our ability to attract and retain highly qualified and experienced management, scientific, and technical personnel. Competition and compensation for such personnel and other qualified personnel have increased the difficulty and cost of hiring and retaining qualified personnel. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our business, and it may have a material adverse effect on our business as a whole. Additionally, disruptions to our supply chain could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation has had, and we expect it will continue to have, an impact on the costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.
31

Table of Contents
The following table represents the balances of cash, cash equivalents and marketable investment securities:

(in millions) | September 30, 2022 |  |  | December 31, 2021 |  | Change
Cash and cash equivalents | $ | 110.7 |  |  |  | $ | 258.4 |  |  | $ | (147.7) |
Marketable investment securities | 82.5 |  |  |  | 81.4 |  |  | 1.1 |
Long-term marketable investment securities | 66.0 |  |  |  | 59.0 |  |  | 7.0 |
Cash, cash equivalents and marketable investment securities | $ | 259.2 |  |  |  | $ | 398.8 |  |  | $ | (139.6) |

The decrease in cash, cash equivalents, and marketable investment securities was primarily driven by $98.6 million in cash used by operations, $30.7 million used for capital expenditures, and $5.2 million used for the payment of withholding tax for the issuance of common stock, net of proceeds from the issuance of common stock.
The following table represents the Condensed Consolidated Cash Flow Statement:

| Nine Months Ended September 30, |  |
(in millions) | 2022 |  |  | 2021 |  | Change
Cash flows provided by (used in) operating activities | $ | (98.6) |  |  |  | $ | 28.1 |  |  | $ | (126.7) |
Cash flows provided by (used in) investing activities | (41.9) |  |  |  | 300.3 |  |  | (342.2) |
Cash flows used in financing activities | (5.9) |  |  |  | (149.5) |  |  | 143.6 |
Effect of foreign exchange rates on cash and cash equivalents | (1.3) |  |  |  | (0.7) |  |  | (0.6) |
Net increase (decrease) in cash and cash equivalents | (147.7) |  |  |  | 178.2 |  |  | (325.9) |
Cash and cash equivalents at the beginning of the period | 258.4 |  |  |  | 117.0 |  |  | 141.4 |
Cash and cash equivalents at the end of the period | $ | 110.7 |  |  |  | $ | 295.2 |  |  | $ | (184.5) |

Cash Flows from Operating Activities
The decrease in cash flows from operating activities for the nine months ended September 30, 2022, compared to the same period in the prior year, was primarily due to the change in the balance of prepaid taxes due to the receipt of an $89.6 million U.S. federal tax refund in the prior period and an $83.4 million decrease in accrued liabilities for the current period, which was primarily driven by legal settlement payments of $62.0 million.
Cash Flows from Investing Activities
The decrease in cash flows from investing activities for the nine months ended September 30, 2022, compared to the same period in the prior year, was primarily due to the $379.1 million cash proceeds from divestitures in the prior period, with no corresponding proceeds in the current period, partially offset by a $50.8 million increase in proceeds from marketable investment securities in the current period.
Cash Flows from Financing Activities
The decrease in cash flows used in financing activities for the nine months ended September 30, 2022, compared to the same period in the prior year, was primarily due to the use of $226.4 million in cash for repayments of the Amended Facility during the nine months ended September 30, 2021, partially offset by a decrease of $86.6 million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax, compared to the same period in the prior year.
Effects of Inflation
Inflation has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies. Inflationary costs have impacted our profitability and continue to adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding.
32

Table of Contents
Critical Accounting Estimates
Critical accounting estimates are those policies which are both important to the presentation of a company’s financial condition and results and require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a further discussion of our critical accounting estimates, see our Annual Report on Form 10-K. No significant changes to our accounting policies took place during the nine months ended September 30, 2022.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We have exposure to various foreign currency exchange rate fluctuations with regard to certain agreements with service providers. While our expenses are predominantly denominated in U.S. dollars, approximately 10% of our revenues are denominated in other currencies, primarily in Japanese yen. A hypothetical 10% change in the value of the Japanese yen relative to the U.S. dollar would result in a 1% change in our revenues. Although we also have certain operations denominated in euros, Swiss francs, and Great British pounds, among other currencies, those operations are subject to less overall market risk due to the revenue and expenses being denominated in the same currency.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (“Disclosure Controls”) within the meaning of Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.
As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2022, our Disclosure Controls are not effective.
Management concluded that, as of December 31, 2021, a material weakness in internal control over financial reporting exists related to general information technology controls for information systems that are relevant to the preparation of the financial statements. Specifically, the material weakness resulted from the aggregation of control deficiencies related to systems supporting the Company's internal control processes. This material weakness has not been remediated as of September 30, 2022. Our IT-dependent business process controls were also deemed ineffective because they could have been adversely impacted. While the aggregation of these deficiencies did not result in any misstatement of the consolidated financial statements, the material weakness could have resulted in a misstatement impacting account balances or disclosures that would have resulted in a material misstatement to the consolidated financial statements that would not have been prevented or detected on a timely basis.
Plan to Remediate Material Weakness
Management is committed to the remediation of the material weakness described above, as well as the continued improvement of our internal control over financial reporting. Management has been implementing, and will continue to implement, measures designed to ensure that our controls are designed, implemented, and operating effectively.
33

Table of Contents
We have begun the process of, and we are focused on, designing and implementing effective internal control measures to improve our internal control over financial reporting and remediate the material weaknesses identified above. Our efforts include the following actions:
Information Technology General Controls ("ITGCs")
•We have conducted and will continue to conduct additional training for our IT personnel to ensure a clear understanding of risk assessment, controls and monitoring activities related to automated processes and systems and ITGCs related to financial reporting.
•We have implemented and continue to implement improved IT policies, procedures and control activities for key systems which impact our financial reporting.
•We are increasing resources dedicated to monitoring ITGCs related to financial reporting, including additional personnel with the appropriate level of knowledge, experience and training, to ensure compliance with policies and procedures.
•We hired a third-party to assist with the implementation of, and to review and provide feedback on, our remediation plan. In addition, the third-party is advising on best practices to further strengthen our IT control environment.
We intend to remediate this material weakness as soon as possible. We will continue to monitor the effectiveness of our controls and will make any further changes that management determines are appropriate.
Remediation of Previously Reported Material Weakness
The material weakness in our internal control over financial reporting related to our income tax provision process identified in connection with the preparation of our condensed consolidated quarterly financial statements as of September 30, 2021 has been remediated. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the income tax provision and related accrual. While the control deficiency did not result in a misstatement of our previously issued consolidated financial statements, the control deficiency could have resulted in a misstatement of the income tax related accounts or disclosures that would have resulted in a material misstatement of our annual or interim consolidated financial statements that would not have been prevented or detected on a timely basis. This material weakness has been remediated as of March 31, 2022.
To improve our internal control over financial reporting and remediate this prior period material weakness, we designed and implemented enhanced controls over the review of information underlying discrete transactions in the income tax provision.
Changes in Internal Controls
There were no changes in our internal control over financial reporting that occurred during the nine months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
34

Table of Contents
PART II - Other Information
Item 1. Legal Proceedings.
For information regarding certain current legal proceedings, see Note 13, "Commitments and Contingencies - Legal Proceedings" in Notes to Condensed Consolidated Financial Statements, which are included herein.
Item 1A. Risk Factors.
In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, other than the updates to the risk factor set forth below. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.
We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.
We receive a portion of our revenues and pay a portion of our expenses in currencies other than the United States dollar, such as the Euro, the Swiss franc, the British pound, the Australian dollar and the Canadian dollar. As a result, we are at risk for exchange rate fluctuations between such foreign currencies and the United States dollar, which could affect the results of our operations. If the U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result in decreased revenues and operating expenses. During the three and nine months ended September 30, 2022, our revenues were negatively impacted by approximately $3.3 million and approximately $7.1 million, respectively, due to foreign currency fluctuations. We may not be able to offset adverse foreign currency impact with increased revenues. We do not currently utilize hedging strategies to mitigate foreign currency risk and even if we were to implement hedging strategies to mitigate foreign currency risk, these strategies might not eliminate our exposure to foreign exchange rate fluctuations and would involve costs and risks of their own, such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million is still available to repurchase as of September 30, 2022. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management’s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. The repurchase program may be suspended or discontinued at any time without prior notice.
No stock repurchases were made under our stock repurchase program during the nine months ended September 30, 2022.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
35

Table of Contents
Item 5. Other Information.
On October 31, 2022, our Board of Directors (the “Board”) approved an increase in the size of the Board from eight to nine members and appointed Paul M. Bisaro to fill the newly created vacancy, effective immediately, to serve as a Class III Director with a term expiring at our 2023 Annual Meeting of Stockholders. The Board has determined that Mr. Bisaro meets the independence requirements of the Nasdaq Stock Market Rules. The Board appointed Mr. Bisaro to serve on the Research and Product Innovation Committee of the Board and the Nominating, Environmental, Social and Governance Committee of the Board, in each case effective immediately.
Mr. Bisaro will be compensated for his service as director on the same basis as our other non-employee directors, as more fully described in our non-employee director compensation policy (the “Non-Employee Director Compensation Policy”), a copy of which is included as Exhibit 10.2 hereto and incorporated by reference herein, as well as the “Director Compensation” section of our definitive proxy statement for the 2022 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 14, 2022. Pursuant to the Non-Employee Director Compensation Policy, in connection with his appointment to the Board, Mr. Bisaro was granted a restricted stock unit award for our shares of common stock having an aggregate value of $350,000. The foregoing grant will vest one year following the grant date. Mr. Bisaro also entered into our standard indemnification agreement for directors.
There are no arrangements or understandings between Mr. Bisaro and any other person pursuant to which he was selected to serve on the Board, and Mr. Bisaro is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.
Item 6. Exhibits.

10.1 | Amendment No. 4, dated July 26, 2022, to the Credit Agreement, dated December 23, 2016, among the Company, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, as amended July 31, 2018, May 1, 2020, and February 22, 2021 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No. 000-26642, filed with the SEC on July 27, 2022). |  |  |  |  |  |  |
10.2+ | Non-Employee Director Compensation Policy+ |  |  |  |  |  |  |
31.1 | Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |
31.2 | Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |
32.1 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished). |  |  |  |  |  |  |
101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |  |
101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |  |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |  |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |  |  |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |  |  |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |  |
104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 has been formatted in Inline XBRL. |  |  |  |  |  |  |

(+) Management contract or compensatory plan arrangement
36

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| MYRIAD GENETICS, INC.
Date: November 2, 2022 | By: | /s/ Paul J. Diaz
|  | Paul J. Diaz
|  | President and Chief Executive Officer
|  | (Principal executive officer)
Date: November 2, 2022 | By: | /s/ R. Bryan Riggsbee
|  | R. Bryan Riggsbee
|  | Chief Financial Officer
|  | (Principal financial officer)
Date: November 2, 2022 | By: | /s/ Natalie Munk
|  | Natalie Munk
|  | Chief Accounting Officer
|  | (Principal accounting officer)

37